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Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α (NFKBIA),  which is a 
tumor suppressor gene,  was found to be silenced in lung adenocarcinomas.  We examined NFKBIA 
expression,  mutations in the EGFR and K-ras genes,  and EML4-ALK fusion in 101 resected lung 
adenocarcinoma samples from never-smokers.  NFKBIA expression was evaluated using immunohis-
tochemistry.  NFKBIA expression was negative in 16 of the 101 samples (15.8ｵ).  EGFR and K-ras 
mutations and EML4-ALK fusion were detected in 61 (60.5ｵ),  1 (1.0ｵ),  and 2 (2.0ｵ) of the 101 sam-
ples,  respectively,  in a completely mutually exclusive manner.  Negative NFKBIA expression was 
observed signiﬁcantly more frequently among the tumors with none of the three genetic alterations 
compared to those with such alterations (p＝0.009).  In addition,  negative NFKBIA expression was 
signiﬁcantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant sam-
ples (p＝0.013).  In conclusion,  NFKBIA expression was silenced in adenocarcinomas without EGFR/
K-ras mutations or EML4-ALK fusion,  suggesting that the silencing of NFKBIA may play an impor-
tant role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-
ALK fusion.
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ung cancer is a leading cause of cancer-related 
deaths worldwide [1].  Although tobacco smok-
ing is an important risk factor for lung cancer,  never-
smokers can also develop lung cancer.  Actually,  lung 
cancer among never-smokers is the seventh most com-
mon cause of cancer-related deaths [2].  Various 
molecular alterations in lung cancer have been 
reported [3],  and recent studies have focused inten-
sively on driver alterations,  such as K-ras and epider-
mal growth factor receptor (EGFR) mutations and EML4-
ALK fusion.  The latter 2 alterations are known to be 
frequent among lung adenocarcinomas arising in never-
smokers.  In addition,  the presence and success of 
eﬀective molecular targeting drugs for patients with 
these alterations make the identiﬁcation of causative 
alterations important and useful.
　 Considerable evidence shows that nuclear factor of 
kappa light chain gene enhancer in B cells (NF-κB) is 
constitutively activated in a variety of solid tumors,  
including prostate,  breast,  cervical,  pancreatic,  and 
lung cancers [4].  NF-κB is a transcription factor 
activated by the EGFR pathway and is repressed by 
NF-κB inhibitor α (NFKBIA).  It is encoded by 
NFKBIA located at 14q13 [5].  Hence,  NFKBIA is 
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considered a tumor suppressor gene.  NFKBIA is 
reportedly deleted in glioblastomas.  The deletion of 
NFKBIA and the ampliﬁcation of EGFR show a pattern 
of mutual exclusivity [6].
　 In the present study,  we determined the expression 
status of NFKBIA using immunohistochemistry (IHC) 
staining,  and we examined the incidence of EGFR and 
K-ras mutations and EML4-ALK fusion to investigate 
the inter-relationship among these genetic alterations 
and clinical factors in never-smokers with lung adeno-
carcinoma.
Materials and Methods
　 Patients. We obtained 101 lung adenocarci-
noma samples from never-smokers who underwent 
surgical resections at our hospital between September 
2004 and June 2008.  Never-smokers were deﬁned as 
patients who had smoked ＜100 cigarettes in their 
lifetime.  Smoking history was obtained by a direct 
interview.  The patient characteristics are summa-
rized in Table 1.  The institutional review board 
approved this study,  and informed consent was 
obtained from all the patients.
　 NFKBIA Immunohistochemistry. For the 
IHC,  4-µm sections were cut from paraﬃn-embedded 
tissue specimens and placed on MAS-GP type A 
coated glass slides (Matsunami Glass,  Osaka,  Japan).  
The slides were then deparaﬃnized in xylene and 
rehydrated in a graded series of ethanol (100ｵ,  
100ｵ,  90ｵ,  70ｵ,  and 50ｵ).  After the antigens 
were revealed with 10mM sodium citrate (pH6.0),  the 
slides were incubated in 3ｵ H2O2 for 10min to block 
endogenous peroxidase.  To inhibit nonspeciﬁc binding,  
the samples were incubated in diluted normal horse 
serum for 30min.  After blocking,  the slides were 
incubated with NFKBIA antibody (Abcam,  Cambridge,  
UK; diluted 1 : 50 in PBS) at 4℃ overnight.  The 
slides were washed in PBS for 5min and incubated in 
secondary antibody (ImmPRESS Anti-Rabbit Ig per-
oxidase Polymer Detection Kit; Vector Laboratories,  
Peterborough,  UK) for 30min at room temperature.  
The slides were stained with 3, 3ʼ-diaminobenzidine 
(DAB Substrate Kit,  Vector Laboratories) and were 
counterstained with Mayerʼs hematoxylin [7,  8].
　 Two investigators (MF and KI) who were unaware 
of the clinical data independently evaluated the marker 
staining under a light microscope at ×400 magniﬁca-
tion.  We deﬁned positive NFKBIA protein expression 
as ｧ10ｵ of the tumor cells exhibiting cytoplasmic or 
membranous staining according to our previous IHC 
study regarding EGFR protein [9] (Fig.  1).
　 DNA and RNA extractions. Genomic DNA 
was obtained from primary tumors using standard 
phenol-chloroform (1 : 1) extraction,  followed by etha-
nol precipitation,  or by using the DNeasy Tissue Kit 
(Qiagen,  Valencia,  CA,  USA).  Total RNA was 
extracted from the primary tumors using the RNeasy 
mini Kit (Qiagen) according to the manufacturerʼs 
protocol.  Oligo(dT)-primed cDNA was synthesized 
using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems,  Foster City,  CA,  USA) 
with DNase treatment.
　 Detection of EGFR and K-ras mutations and 
EML4-ALK fusion events. The EGFR muta-
tional status was determined using a mutant non-
enriched PCR assay,  as reported [10].  Brieﬂy,  the 
common deletions of exon 19 were distinguished from 
the wild type based on PCR product length polymor-
phisms using 12ｵ polyacrylamide gel electrophoresis 
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Table 1　 Patient characteristics
Variables No. of patients (%) (n＝101)
Age
Mean (range)  67.0 (39-89)
＜67 years  49 (48.5)
ｧ67 years  52 (51.5)
Sex
Male  16 (15.8)
Female  85 (84.2)
Pathological stage
I  87 (86.1)
II 　4 (4.0)
III 　8 (7.9)
IV 　2 (2.0)
NFKBIA IHC
Positive  85 (84.2)
Negative  16 (15.8)
EGFR mutation
Mutant  61 (60.4)
WT  40 (39.6)
K-ras mutation
Mutant 　1 (1.0)
WT 100 (99.0)
EML4-ALK fusion gene
Positive 　2 (2.0)
Negative  99 (98.0)
IHC,  immunohistochemistry; WT,  wild type.
(PAGE) via ethidium bromide staining.  For the exon 
21 L858R mutation,  Sau96I digestion,  which speciﬁ-
cally digests the mutant type,  was performed prior to 
12ｵ PAGE.  The K-ras mutations in codons 12 and 
13 were examined using PCR-based direct sequencing 
on an ABI PRISM 3130xl Genetic Analyzer (Applied 
Biosystems),  as reported [11-13].  Screening for 
EML4-ALK fusion was performed using ALK IHC and 
was conﬁrmed using a reverse transcriptional (RT)-
PCR assay.
　 ALK Immunohistochemistry. Unstained 
paraﬃn-embedded sections were depleted of paraﬃn 
with xylene,  rehydrated with a graded series of etha-
nol solutions,  and then subjected to heat-induced 
antigen retrieval with Target Retrieval Solution 
(pH9.0) (Dako,  Glostrup,  Denmark) before IHC 
staining with a mouse monoclonal antibody to ALK 
(ALK1,  1 : 25 dilution; Dako).  Immune complexes 
were detected using a DAB system (Dako) with minor 
modiﬁcations.
　 RT-PCR. The primers that we used to identify 
the EML4-ALK fusion transcript were chosen to 
enable the detection of all possible in-frame fusions of 
EML4 to exon 20 of ALK in which the kinase domain 
of ALK would be preserved.  The forward primers 
used were EML4 72F (5ʼ-GTCAGCTCTTGAGTCA 
CGAGTT-3ʼ) and Fusion-RT-S (5ʼ-GTGCAGTGTTT 
AGCATTCTTGGGG-3ʼ),  and the reverse primer was 
ALK 3078RR (5ʼ-ATCCAGTTCGTCCTGTTCAGA 
GC-3ʼ) [14].  PCR was performed for EML4-ALK 
under the following conditions: 94℃ for 10min,  fol-
lowed by 35 cycles of denaturation at 94℃ for 1min,  
annealing at 64℃ for 1min,  and polymerization at 
72℃ for 1min,  with a ﬁnal extension step at 72℃ 
for 7min.  RT-PCR for GAPDH expression was per-
formed under the same conditions in each tumor sam-
ple as an internal control.
　 Statistical analysis. Diﬀerences between the 
2 groups were assessed using the χ2 test or Fisherʼs 
exact test,  as appropriate.  All of the data were ana-
lyzed using JMP,  version 9.0.0 (SAS Institute Inc.,  
Cary,  NC,  USA).  For each analysis,  probability 
values of less than 0.05 were considered signiﬁcant.
Results
　 NFKBIA expression. NFKBIA expression 
was silenced in 16 (15.8ｵ) of the 101 patients.  
Examples of the IHC staining patterns are illustrated 
in Fig.  1.  The relationships between clinical factors 
and the NFKBIA expression status are detailed in 
Table 2.  No signiﬁcant associations were observed 
between the NFKBIA expression status and any of the 
clinical factors that were examined.
　 EGFR and K-ras mutations and EML4-ALK 
fusion. EGFR mutations were detected in 61 
(60.4ｵ) of the 101 patients; 29 patients had an exon 
19 deletion,  and 32 had an exon 21 mutation (L858R).  
By contrast,  K-ras mutation and EML4-ALK fusion 
were observed in 1 (1ｵ) and 2 (2ｵ) of the 101 
patients,  respectively.  The relationships between the 
clinical factors that were examined and the EGFR and 
K-ras mutation and EML4-ALK fusion statuses are 
shown in Table 2.  The incidences of EGFR mutations 
according to age or gender were not signiﬁcantly dif-
ferent.
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Fig. 1　 Representative results of NFKBIA IHC and expression levels.  A,  Positive staining for NFKBIA; B,  Negative staining for 
NFKBIA.
　 Inter-relationships among the molecular 
alterations. Negative NFKBIA expression was 
found to be signiﬁcantly more frequent among the 
EGFR wild-type patients compared to the EGFR 
mutant patients (p＝0.013),  whereas no correlation 
was observed between the NFKBIA expression level 
and the K-ras mutation or EML4-ALK fusion status 
(Table 3).  Negative NFKBIA expression appeared 
signiﬁcantly more frequently in the tumors without any 
of these three genetic alterations compared to those 
with a genetic alteration (p＝0.009).
Discussion
　 In this study,  NFKBIA expression was repressed 
in some subsets of the lung adenocarcinomas.  
NFKBIA can be inactivated through several mecha-
nisms.  Although the deletion of NFKBIA has been 
identiﬁed,  14q13―which is the locus of NFKBIA―
is not frequently deleted in non-small cell lung cancer 
(NSCLC) [15].  In cancer epigenetics,  aberrant CpG 
methylation in the promoter region is a key mechanism 
for gene inactivation,  resulting in tumorigenesis in 
human malignancies including lung cancer [16,  17].  
Thus,  we analyzed the methylation of NFKBIA using 
lung cancer cell lines in which NFKBIA expression 
was repressed.  However,  we did not detect methyla-
tion in the cell lines that were tested (data not shown).
　 Although a mutation of NFKBIA has been reported 
[18],  such mutations are rare.  Epidermal growth 
factor (EGF) induces NFKBIA degradation by phos-
phorylation at tyrosine 42,  resulting in the activation 
of NF-κB.  Interestingly,  the HCC827 and H3255 cell 
lines,  which have EGFR mutations causing the consti-
tutive activation of the EGFR pathway,  exhibit the 
EGF-independent activation of NF-κB [19].
　 Our ﬁndings indicate that the NFKBIA silencing 
tended to occur more frequently in EGFR wild-type 
adenocarcinomas,  which is similar to the results regard-
ing glioblastoma reported by Bredel et al. [6].  
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Table 2　 Relationships among clinical factors and genetic alterations
Variables NFKBIA
＋ / －
P EGFR
＋ / －
P K-ras
＋ / －
P EML4 -ALK
＋ / －
P
Age
　＜67 years (n＝49) 40 /  9 0.7 27 / 22 0.4 1 / 48 0.5 2 / 47 0.2
　ｧ67 years (n＝52) 45 /  7 34 / 18 0 / 52 0 / 52
Sex
　Male (n＝16) 12 /  4 0.5 11 /  5 0.6 0 / 16 1.0 0 / 16 1.0
　Female (n＝85) 73 / 12 50 / 35 1 / 84 2 / 83
Pathological stage
　I (n＝87) 71 / 16 0.2 51 / 36 0.5 1 / 86 1.0 2 / 85 1.0
　II-IV (n＝14) 14 /  0 10 /  4 0 / 14 0 / 14
Table 3　 Inter-relationships among the 4 genetic alterations
Variables NFKBIA
＋ / －
P EGFR
＋ / －
P K-ras
＋ / －
P EML4 -ALK
＋ / －
P
NFKBIA ＋ 56 / 29 0.013 1 / 84 1 2 / 83 1
－ 5 / 11 0 / 16 0 / 16
EGFR ＋ 56 /  5 0.013 0 / 61 0.4 0 / 61 1
－ 29 / 11 1 / 39 2 / 38
K-ras ＋ 1 /  0 1 0 /  1 0.4 0 /  1 1
－ 84 / 16 61 / 39 2 / 98
EML4 -ALK
＋ 2 /  0 1 0 /  2 0.15 0 /  2 1
－ 83 / 16 61 / 38 1 / 98
Negative NFKBIA expression occurred signiﬁcantly more frequently in tumors without any of the 3 genetic alterations than in those with an 
alteration (p＝0.009).  In addition,  negative NFKBIA expression was observed signiﬁcantly more frequently among EGFR wild-type patients 
than among EGFR mutant patients (p＝0.013).
Moreover,  negative NFKBIA expression was signiﬁ-
cantly more frequent in the tumors without EGFR,  
K-ras or EML4-ALK genetic alterations than in those 
with such a genetic alteration.  These ﬁndings indicate 
that the silencing of NFKBIA may play a pivotal role 
in the lung adenocarcinomas of never-smokers without 
EGFR,  K-ras,  or EML4-ALK genetic alterations.
　 Both chemotherapeutics and radiation induce NF-
κB activation in cancer cells,  contributing to the 
development of resistance to these therapies [20].  
Considering the above-mentioned knowledge and our 
present ﬁndings,  targeting the NF-κB pathway―
including NFKBIA―is a potential therapeutic option 
for the treatment of NSCLC patients,  especially for 
those without EGFR,  K-ras,  or EML4-ALK altera-
tions.
　 Although we observed negative NFKBIA expres-
sion more frequently in the EGFR wild-type adenocar-
cinomas,  we also detected negative NFKBIA expres-
sion in ﬁve EGFR-mutant cases.  Bivona et al. reported 
that NF-κB activation through the downregulation of 
NFKBIA confers EGFR- tyrosine kinase inhibitor 
(TKI) resistance in EGFR-mutant lung cancers with 
EGFR-TKI treatment [21].  Regarding the above-
mentioned ﬁve cases,  no data of EGFR-TKI sensitiv-
ity were available because no recurrence has been 
observed after the patientsʼ surgery.  We sometimes 
encounter patients who are resistant to EGFR-TKI 
although they have TKI-sensitive EGFR mutations 
without T790M mutation,  MET ampliﬁcation or other 
known resistance-related alterations.  In such cases,  it 
may be preferable to examine the alteration of 
NFKBIA.
　 A limitation of this study is that the evaluation of 
NFKBIA expression was done only by IHC.  We may 
have to conﬁrm the expression status of NFKBIA by 
other methods such as western blotting,  although 
there is a technical diﬃculty because of the contami-
nation of normal cells in clinical tumor samples.  In 
addition,  we did not perform an in vitro assay to exam-
ine the functional importance of NFKBIA loss in 
EGFR wild-type lung cancer.  Further investigation is 
needed to clarify the impact of silenced NFKBIA 
expression in lung cancer.
　 In conclusion,  our ﬁndings suggest that the loss of 
NFKBIA expression is a frequent event in lung adeno-
carcinomas of never-smokers and may mediate an 
important non-tobacco carcinogenic pathway,  particu-
larly in lung adenocarcinomas with wild-type EGFR.
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